Sanofi set to buy Bioverativ for more than $11.5 billion: WSJ

The potential deal, which could be announced as soon as Monday, would value Bioverativ at about $105 a share, the Journal reported. (http://on.wsj.com/2mYJulp)

The price represents a 64 percent premium to Bioverativ stock's close on Friday on the Nasdaq.

Bioverativ, a hemophilia drug maker, was separated from Biogen Inc early last year.

Sanofi has failed to land major deals after losing California-based cancer specialist Medivation to Pfizer Inc in 2016 and Swiss biotech company Actelion to Johnson & Johnson last year.

Earlier this month, Sanofi said it obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with Alnylam Pharmaceuticals.

Sanofi and Bioverativ were not immediately available for comment outside regular business hours.

(Reporting by Shubham Kalia in Bengaluru; Editing by Paul Simao and Gopakumar Warrier)